Immunosuppressive tor kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

Transplantation

Volumn 75, Issue 10, 2003, Pages 1710-1717

  Majewski, Miroslaw ^a   Korecka, Magdalena ^a   Joergensen, Joanne ^b   Fields, Leona ^a   Kossev, Plamen ^a   Schuler, Walter ^b   Shaw, Leslie ^a   Wasik, Mariusz A ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; TOR KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; GRAFT REJECTION; GROWTH INHIBITION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SCID MOUSE; XENOGRAFT;

ANIMALS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CELL TRANSPLANTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED STRAINS; MICE, SCID; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIROLIMUS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0038054547     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000063934.89714.19     Document Type: Article

References (32)

1. Swierdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14: 2-7.
2. Hsieh WS, Lemas MV, Ambinder RF. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. Transpl Infect Dis 1999; 1: 204-212.
3. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60-69.
4. Tao J, Wasik MA. Epstein-Barr Virus associated polymorphic lymphoproliferative disorders occurring in non-transplant settings. Lab Invest 2001; 81: 429-437.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
6. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998; 30: 2192-2194.
7. Hausen B, Ikonen T, Briffa N, et al. Combined immunosuppression with cyclosporine (Neoral®) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69: 76-86.
8. Schuurman HJ, Ringers J, Schuler W, et al. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737-742.
9. Majewski M, Korecka M, Kossev P, et al. Immunosuppressive macrolide RAD inhibits growth of human EBV-transformed B lymphocytes in vitro and in vivo; a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97: 4285-4290.
10. Kossev P, Raghunath PN, Schuster S, et al. Differential expression of SHP-1 by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts. Am J Surg Pathol 2001; 25: 949-955.
11. Paessler M, Kossev P, Raghunath P, et al. SHP-1 expression correlates with post-germinal center cell derivation of post-transplant lymphoproliferative disorders. Lab Invest 2001; 81: 1029.
12. Silberstein LE, Jefferies LC, Goldman J. Variable region gene analysis of pathologic human autoantibodies to the related I and I red blood cells antigens. Blood 1991; 78: 2372-2386.
13. Zhang Q, Lee B, Korecka M, et al. Differences in phosphorylation of the IL-2R associated Jak/STAT proteins between HTLV-I(+), IL-2 independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia (ATLL). Leuk Res 1999; 23: 373-384.
14. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A 1996; 93: 9148-9153.
15. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343-350.
16. Seghal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action; immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
17. Kawamata S, Sakaida H, Hori T, et al. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998; 91: 561-569.
18. Benkerrou M, Jais J-P, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137-3147.
19. Oertel SH, Ruhnke MS, Anagnostopoulos I. Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 1999; 67: 765-767.
20. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999; 96: 10391-10396.
21. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-814.
22. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54: 815-824.
23. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59: 3-16.
24. Aaguaard-Tillery KM, Jelinek D. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 1994; 152:493-507.
25. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor phase-I by the mammalian target of rapamycin. Science 1997; 277: 99-101.
26. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886-894.
27. Sakata A, Kuwahara K, Ohmura T, et al. Involvement of a rapamycinsensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol Lett 1999; 68: 301-309.
28. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000; 60: 3504-3513.
29. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001; 98: 136-141.
30. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001; 21: 5050-5062.
31. Ozes ON, Akca H, Mayo LD, et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A 2001; 98: 4640-4645.
32. Zhang Q, Raghunath PN, Vonderheid E, et al. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000; 157: 1137-1146.